Computed Tomography in Nonalcoholic Fatty Liver Disease
- 143 Downloads
The value and/or limitations of computed tomography (CT) in assessment of hepatosteatosis are not well studied in nonalcoholic fatty liver disease (NAFLD). We prospectively evaluated the accuracy of CT in assessing the amount of hepatosteatosis in NAFLD patients and the impact of demographic and histopathologic variables on CT images. Forty patients with biopsy-proven NAFLD were eligible. Of these, 10 exhibited hepatic iron overload. Liver and spleen attenuation measurements were obtained and spleen-minus-liver attenuation difference (ΔS–LA) was calculated. A good correlation between ΔS–LA and pathological hepatosteatosis was observed (r = 0.837, P < 0.0001). Liver iron overload did not affect this correlation, although the mean ΔS–LA was significantly lower in patients with iron overload. No correlation was detected between ΔS–LA and hepatic inflammation, fibrosis, or body mass index. We conclude that ΔS–LA derived from CT may be a useful tool for predicting the amount of hepatosteatosis in NAFLD patients as it is not affected by various individual factors.
Key Wordsnonalcoholic steatohepatitis nonalcoholic fatty liver disease spleen-minus-liver attenuation difference hepatic iron overload computed tomography
Unable to display preview. Download preview PDF.
- 1.Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, Paolis P, Capussotti L, Salizzoni M, Rizzetto M: Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134–140, 2002CrossRefPubMedGoogle Scholar
- 2.AGA: AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123:1705–1725, 2002Google Scholar
- 4.Duman DG, Tüney D, Çelikel Ç, Avşar E, Akpinar I, Bekiroglu N, Tözün N: Value of computed tomography in nonalcoholic steatohepatitis (NASH); comparison with liver biopsy. J Hepatol 34 (Suppl 1):195A, 2001Google Scholar
- 6.Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR: Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 38:434–440, 2003CrossRefPubMedGoogle Scholar
- 7.KiyiciM, Gülten M, Gürel S, Nak SG, Dolar E, Savcí G, Adím SB, Yerci Ö, Memik F: Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 17:713–718, 2003Google Scholar
- 8.Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: an expanded clinical entity. Gasroenterology 107:1103–1109, 1994Google Scholar
- 11.Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G: Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 96:2448–2455, 2001CrossRefPubMedGoogle Scholar
- 13.Mendler MH, Bouillet P, LeSidaner A, Lavoine E, Labrousse F, Sautereau D, Pillegand B: Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. J Hepatol 28:785–794, 1998CrossRefPubMedGoogle Scholar
- 16.Baron RL, Freeny PC, Moss AA: The liver. In. Computed Tomography of the Body with Magnetic Resonance Imaging. Moss AA, Gamsu G, Genant HK (eds). Philadelphia, WB Saunders, 1992, pp 735–821Google Scholar